Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of human cancer. It is basically resistant to all mainstream cancer treatment modalities, such as chemotherapy and radiotherapy, and a surgical resection is effective for only 15-25% of patients [1]. A key to a successful therapy could be individualized treatment, which employs new pancreatic cancer cell lines, derived from patient tissue. Such lines represent a clinically relevant in vitro model of a tumor and can be used for drug testing.
In this study we present a new pancreatic cancer cell line Capan-26, which was derived from PDAC tissue of a 65-year old female Lithuanian patient. We determined cell doubling time and showed expression of E-cadherin and two PDAC markers CEACAM6 and CA19-9 in 2D and 3D Capan-26 culture. Ras sequencing detected a point mutation E76→K76, which is claimed to be oncogenic in both in vitro and in vivo PDAC models [2]. We believe that Capan-26 will be a valuable tool for human PDAC studies in the future.